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Abstract

The role of beta-adrenergic receptor antagonists in cardiovascular therapy has been the
subject of various studies over time, these agents representing one of the oldest class of
drugs used for the treatment of cardiovascular diseases. Although beta-blockers have been
excluded from guidelines as the first-line therapy in essential hypertension, they remain
the first choice in patients with heart failure, coronary artery disease, and atrial fibrillation.
In this article, we review the major clinical evidence for the use of beta-blockers in
cardiovascular diseases.
Several trials have demonstrated that beta-blockers reduce mortality in patients with
heart failure with a reduced ejection fraction. Also, beta-blockers have beneficial
properties in patients with heart failure with preserved ejection fraction. Guidelines
recommend beta-blockers for the relief of symptoms in cases of angina pectoris and for
the control of the ventricular rate in cases of atrial fibrillation. Also, beta-blockers have
numerous benefits in hypertensive patients with diabetes mellitus. In conclusion, betablockers are an important class of cardiovascular drugs, reducing the mortality and
morbidity rates in patients with cardiovascular diseases.
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✓ Beta-adrenoreceptor antagonists (beta-blockers) are an important class of cardiovascular
medications, used for decades in patients with arterial hypertension, chronic heart failure,
and coronary artery disease, representing the cornerstone therapy.
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✓ Guidelines recommend beta-blockers for the relief of symptoms in cases of angina pectoris
and in the control of the ventricular rate in cases of atrial fibrillation.
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Introduction
Beta-adrenoreceptor antagonists (beta-blockers) are an
important class of cardiovascular medication, used for
decades in patients with arterial hypertension, chronic heart
failure, and coronary artery disease, representing the
cornerstone therapy in these cases (1). Studies have
consistently demonstrated that agents such as bisoprolol,
carvedilol, and metoprolol reduce hospitalizations in
patients diagnosed with heart failure NYHA functional
class II to IV (2). Beta-blockers also represent the first-line
therapy in patients with hypertension associated with heart
failure and/or coronary artery disease (3).

Discussions

The Metoprolol Atherosclerosis Prevention in
Hypertensives (MAPHY) study was a trial on 3,234
hypertensive patients investigating the effects of
metoprolol in reducing cardiovascular complications of
hypertension compared to thiazide diuretics. Patients who
received metoprolol had a lower risk of experiencing
cardiovascular events, compared to patients treated with a
thiazide diuretic (9).
Table 1. Classification of beta-blockers (2)
Non-selective
beta-blockers
(both beta1- and
beta 2- receptor
antagonism)

Mechanisms of action
Beta-adrenoreceptor antagonists reduce the activity
of the sympathetic nervous system through the blockade of
beta-receptors, such as beta1-, beta2- and beta3 receptors
(1) (Table 1).
Beta1–adrenergic receptors are found preferentially
in the heart and the renal juxtaglomerular apparatus. Beta1receptors have less influence on vascular muscles (4). The
blockade of this subtype of beta-receptors results in
bradycardia and increased diastolic coronary filling time,
with reduced heart oxygen requirement. These effects are
beneficial in cases of heart failure and myocardial ischemia
(5). Bisoprolol and nebivolol are the agents with the
highest beta1 selectivity effect (3).
Beta2-adrenergic receptors are found in the smooth
muscles of the blood vessels, their stimulation resulting in
vasodilation (6).
Beta3-adrenergic receptors are localized in the heart
and adipocytes, their blockade with nonselective betareceptor antagonists result in weight gain and other
metabolic effects, such as hyperglycemia (5).
Cardioselectivity, or beta1- and beta2- receptor
selectivity, is the characteristic of beta-receptor antagonists
to block beta1 or beta 2 adrenergic receptors preferentially.
Atenolol and bisoprolol are cardioselective beta-blockers,
having an affinity for beta1-adrenergic receptors (7). These
subtypes of beta1-receptors are associated with reduced
cardiac output and also with reduced heart rate and

Propranolol
Carvedilol (with additional alfa1receptor blocking activity)
Labetalol (with additional alfa1receptor blocking activity)
Nadolol
Pindolol
Sotalol
Timolol

Beta1-selective
beta-blockers

Bisoprolol
Metoprolol
Nebivolol
Esmolol
Acebutolol
Atenolol

contractility (6). The Medical Research Council for the
treatment of hypertension in the elderly conducted a

The third generation of beta-receptor antagonists,
such as carvedilol, labetalol, and nebivolol, have
vasodilating effects (10). Carvedilol and labetalol have
vasodilating effects through the association of alphareceptor blockade and the result is represented by a
decreased peripheral vascular resistance (3). These
vasodilating properties are associated with other effects
such as decreased ventricular preload and afterload (6).
Messerli et al. noticed that beta-blockers are
associated with metabolic disorders, such as weight gain
and an increased incidence of new-onset diabetes (11). In
2007, in a meta-analysis which included 94,492 patients
treated with beta-blockers, Bangalore et al demonstrated
that beta-receptor antagonists are associated with low
insulin sensitivity, 22% of patients treated with betablockers being diagnosed with new-onset diabetes (12).
In 2009, Manrique et al. also reported that betablockers are associated with erectile dysfunctions in up to
20% of the patients treated with beta-blockers (13).

randomized trial which enrolled 4,396 hypertensive
patients treated with atenolol. In this trial, atenolol was
associated with a significant reduction in cardiovascular
events over a period of 5 years (8).

Beta-blockers in heart failure
The administration of beta-blockers is recommended
in patients with heart failure, these agents being associated
with lower mortality and morbidity rates (7). Trials and
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major studies with bisoprolol, carvedilol, and metoprolol,
administered to patients diagnosed with heart failure, have
revealed a decreasing incidence of mortality and morbidity
(14).
Heart failure is associated with arterial hypertension.
Bui et al. concluded that 75% of heart failure cases are
preceded by hypertension (15). In a 2011 article on this
topic, Gheorghiade et al. highlighted the importance of the
use of beta-blockers in heart failure (16). The authors
confirmed that beta-blockers reduce the heart rate, have
anti-ischemic effects, and inhibit the release of
angiotensin-converting enzymes (ACE) (14). Also, by
blocking the sympathetic activity, beta-blockers are
associated with the improvement of the ventricular
function and of the hemodynamic parameters (7).
In 2003, a randomized trial by Nodari et al. noted that
beta-blockers are associated with a decreased pressure in
the pulmonary artery and improvement of the left
ventricular ejection fraction in patients with diastolic heart
failure (17). Moreover, the administration of beta-blockers
to patients with heart failure for a long period of time has
been associated with the improvement of hemodynamic
parameters (16).
Guidelines of the European Society of Cardiology
(ESC) and the American Heart Association (AHA)
recommend the administration of beta-blockers associated
with ACE inhibitors to reduce hospitalizations in patients
with heart failure (18). Also, in cases of patients with heart
failure and atrial fibrillation, beta-blockers are the first-line
treatment to control the heart rate (10). Guidelines
recommend the use of beta-blockers to reduce mortality in
hypertensive patients who associate myocardial infarction
in their history (11). The ESC guidelines on peripheral
artery disease recommend beta-blockers for patients
diagnosed with heart failure who associate peripheral
artery disease, because symptoms of intermittent
claudication are not affected by beta-blockers (19).
However, in patients with peripheral arterial disease, the
administration of selective beta-blockers with peripheral
vasodilator action, such as nebivolol, is preferred. Also,
nebivolol stimulates nitric oxide synthase, resulting in
increased levels of nitric oxide, with vasodilating effects
(16).
Randomized trials that investigated the effects of
beta-blockers in heart failure demonstrated that these
agents are associated with a decreased risk of mortality and
hospitalizations (20).
The Cardiac Insufficiency Bisoprolol Study (CIBISII) was a randomized trial conducted in 1999 in Europe
(21). This study enrolled 2,647 patients with heart failure
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NYHA functional class III or IV with reduced ejection
fraction, who were treated with bisoprolol. The trial was
interrupted early because bisoprolol demonstrated a
significant reduction in mortality, compared to placebo.
This trial confirmed that in patients with heart failure, betablockers improve the left-ventricular function (20).
The Carvedilol Prospective Randomized Cumulative
Survival (COPERNICUS) was a trial performed on 2,289
patients diagnosed with heart failure and reduced ejection
fraction (22). This study investigated the role of carvedilol
in patients with systolic heart failure for a period of 10
months and observed that the use of carvedilol is associated
with a relief of heart failure symptoms and decreased
hospitalizations. The mortality rate in this study was
reduced by 35% for patients treated with carvedilol (20).
Also, the Metoprolol Randomised Intervention Trial
in Congestive Heart Failure (MERIT-HF) was conducted
between1997-1998 and enrolled 3,991 patients diagnosed
with heart failure NYHA functional class III-IV (23). This
study investigated the role of metoprolol in addition to
standard therapy in cases of heart failure. The results
showed that metoprolol significantly reduced the mortality
rate (24).
The Study on the Effects of Nebivolol Intervention on
Outcomes and Rehospitalization in Seniors with Heart
failure (SENIORS) enrolled 2,128 patients over 70 years
old, diagnosed with heart failure. This trial showed that
nebivolol is associated with reduced mortality and
morbidity and reduced hospitalization in 14% of the cases,
compared to placebo (25).
The Carvedilol or Metoprolol European Trial
(COMET) was a randomized controlled trial on 3,029
patients that compared the benefits of carvedilol or
metoprolol in patients with chronic heart failure. The
investigators observed that carvedilol reduces mortality of
cardiovascular causes, the risk of sudden cardiac death, and
the incidence of stroke and myocardial infarction,
compared to metoprolol (26).
In a study by Bohm et al. in 2011, which enrolled
patients with heart failure, it was noted that the
administration of beta-blockers before admission to the
hospital and after discharge was associated with lower
mortality in patients with acute decompensation of heart
failure (27).
Also, in cases of patients with heart failure with
preserved ejection fraction, the ESC and AHA guidelines
recommend the administration of beta-blockers (28).
Studies on this topic have demonstrated that beta-blockers
are associated with reduced mortality in these cases (25).
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Moreover, a meta-analysis on this topic conducted by
Bavishi et al. in 2015 noted that beta-blockers are
associated with reduced mortality in patients with heart
failure (29).
Beta-blockers in arterial hypertension and diabetes
It is well known that hypertension is associated with
an increased risk of heart failure, stroke, and renal disease,
and thus, a good therapeutic control of blood pressure is
essential (30).
The Medical Research Council for the treatment of
hypertension in the elderly conducted a trial on 4,396
hypertensive patients treated with hydrochlorothiazide or
atenolol (31). This trial found that hydrochlorothiazide is
associated with a lower risk of cardiovascular events than
atenolol (20). On the other hand, the Heart Attack Primary
Prevention in Hypertension (HAPPHY) trial, performed on
6,569 patients, compared the benefits of the use of diuretics
versus beta-blockers in hypertensive patients. This study
showed no additional benefits between beta-blockers
versus thiazide diuretics in cardiovascular prognosis (32).
Also, atenolol was compared to losartan in the
Losartan Intervention for Endpoint Reduction (LIFE) trial,
performed on 9,193 hypertensive patients. In this trial, the
beneficial effects of atenolol compared to losartan in
hypertensive patients with left ventricular hypertrophy
were investigated, with results showing no differences
between the two groups (33).
Studies demonstrated that metoprolol has more
benefits in hypertensive patients (34). The Metoprolol
Atherosclerosis Prevention in Hypertensives (MAPHY)
trial, which investigated the benefits of metoprolol versus
thiazide diuretics in hypertensive patients with risk factors
for coronary disease discovered that the treatment with
metoprolol in these cases reduces the risk of coronary
events. The results showed that treatment with metoprolol
is associated with a lower incidence of cardiovascular
events (35).
Diabetes mellitus is associated with an increased risk
of developing cardiovascular diseases and the association
with hypertension doubles the risk. In patients with
diabetes mellitus, the risk of heart diseases is two times
higher compared to patients without diabetes (36).
The ESC and AHA guidelines recommend all
classes of antihypertensive therapy in hypertensive patients
who associate diabetes mellitus. Also, beta-blockers are
recommended in diabetic patients with acute myocardial
infarction (29). In diabetic patients with prior myocardial
infarction, beta-blockers reduce the incidence of
arrhythmias, sudden cardiac death, and the recurrence of
cardiac ischemic events (37). Kjekshus et al. discovered

that diabetic patients treated with beta-blockers have a 10%
mortality rate compared to 23% in patients who are not
receiving beta-blockers (38). Guidelines recommend the
use of beta-blockers in patients with diabetes and heart
failure to reduce hospitalization and mortality (36).
Although beta-blockers have negative metabolic
effects, with increased insulin resistance, guidelines
recommend the administration of beta-blockers in diabetic
patients because the adverse metabolic effects are fewer
than the benefits in these cases (39). Trials on this issue
found that a good control of hypertension is more
important in these patients, having macrovascular and
microvascular benefits (40). The UK Prospective Diabetes
Study investigated the effects of blood pressure control in
hypertensive patients who associate diabetes, after 9 years
of follow-up. In this study, the administration of atenolol
was associated with a lower risk of microvascular and
macrovascular complications in 32% of the cases (41).
Beta-blockers and coronary artery disease
Beta-blockers represent the main class of drugs in
patients with coronary artery disease, having multiple
benefits. The effects of beta-blockers in these cases are
based on their negative inotropic and chronotropic
properties. Beta-blockers reduce heart rate, contractility,
and systolic blood pressure, resulting in reduced
myocardial oxygen requirements. Also, beta-blockers
prolong the diastolic filling time, with improved coronary
perfusion (42). Beta-blockers increase the perfusion of the
hibernating ischemic myocardial areas and reduce the
myocardial wall stress, with a low risk of myocardial
rupture after acute myocardial infarction (38, 43).
In patients diagnosed with angina pectoris, betablockers are the essential treatment, reducing the
symptoms and preventing cardiovascular events. Betablockers are recommended for the control of angina
symptoms in patients with coronary artery disease (44, 45).
Beta-receptor antagonists are recommended in
patients with silent ischemia and with a large area of
ischemic myocardial tissue (42). Also, beta-blockers are
used in cases of microvascular angina. Cardioselective
beta1-receptor antagonists are used most frequently in
patients diagnosed with coronary artery disease (37).
A study performed in 2001 by Gotlieb et al., which
enrolled 69,000 patients with prior myocardial infarction
treated with beta-blockers, demonstrated that the use of
beta-receptor antagonists was associated with increased
survival rates in 40% of the patients (46). It was noticed
that in cases of stable angina pectoris, the use of betablockers is associated with symptom relief.
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A meta-analysis conducted by Huang et al. in 2012
assessed the impact of beta-blockers on the mortality rate
in cases of stable angina pectoris and concluded that
cardioselective beta-blockers improve survival rates (47).
Data from the literature state that beta-blockers have
a protective role regarding the recurrence of cardiovascular
ischemic events (48). In an analysis performed by
Bangalore et al. in 2014, patients with prior myocardial
infarction treated with beta-blockers were at lower risk of
recurrent myocardial infarction, although the mortality
rates were not improved (49).
The COMMIT trial (ClOpidogrel and Metoprolol in
Myocardial Infarction Trial) was a randomized trial which
investigated the role of intravenous and oral administration
of metoprolol in 45,852 patients with acute myocardial
infarction from 1,250 hospitals in China, between19992005 (50). This trial showed that the early use of betablockers in acute myocardial infarction reduces the rates of
re-infarction and ventricular arrhythmia, but the risk of
cardiogenic shock remains high (49), especially in patients
above 70 years old, with a systolic blood pressure <120
mmHg and in patients with myocardial infarction Killip
class III (31).
Also, beta-blockers have beneficial effects in patients
with acute myocardial infarction and heart failure with a
reduced ejection fraction. CAPRICORN (CArvedilol PostInfaRct SurvIval COntRolled evaluatioN) was a 2001 trial
enrolling 1,959 patients from 17 countries, with a followup of 1.3 years (50). This trial investigated the effect of
carvedilol after myocardial infarction in patients with left
ventricular dysfunction, demonstrating that the treatment
with carvedilol was associated with decreased mortality in
these cases (51).
Beta-blockers and heart rate control
Atrial fibrillation is the most common arrhythmia in
clinical practice and it is associated with increased risks of
morbidity and mortality. Hypertension, ischemic
cardiomyopathy, valvular disease, and thyroid diseases are
risk factors for the development of atrial fibrillation (27,
52, 53).
Beta-adrenergic receptor antagonists are included in
class II antiarrhythmic agents. Their benefit in atrial
fibrillation is the ventricular rate control. They act by
blocking the effects of catecholamine hormones on beta1adrenergic receptors, resulting in a decreased sympathetic
activity of the heart. Also, beta-blockers decrease the
atrioventricular conduction through the atrioventricular
node (33).
The ESC guidelines recommend that patients with
atrial fibrillation be treated with beta-blockers in order to
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achieve ventricular rate control and to regulate the irregular
heart rhythm (50). The oral administration of beta-blockers
is recommended to control the ventricular rate in patients
with persistent or permanent atrial fibrillation (54).
Also, beta-blockers are recommended for the
prevention of atrial fibrillation in patients with
hypertrophic cardiomyopathy. The AHA guidelines
recommend the use of beta-blockers to control the
ventricular rate in patients with heart failure and acute
coronary syndrome, without high risks of cardiogenic
shock (55).
The AFFIRM trial (the Atrial Fibrillation Follow-up
Investigation of Rhythm Management) was a multicenter
trial, which enrolled 4,060 patients diagnosed with nonvalvular atrial fibrillation (56). This trial compared ratecontrol and rhythm-control strategies for the treatment of
atrial fibrillation. The results showed that beta-blockers
have beneficial effects for the ventricular rate control in
70% of patients with atrial fibrillation (57).

Conclusions
The benefit of the use of beta-blockers in
cardiovascular diseases has been confirmed in numerous
trials. These trials have demonstrated that beta-blockers
reduce mortality in patients with heart failure with a
reduced ejection fraction. Also, beta-blockers have
beneficial properties in patients with heart failure with
preserved ejection fraction. Guidelines recommend betablockers for the relief of symptoms in cases of angina
pectoris and for the control of the ventricular rate in cases
of atrial fibrillation. Also, beta-blockers have numerous
benefits in hypertensive patients with diabetes mellitus. In
conclusion, beta-blockers are an important class of
cardiovascular drugs, reducing the mortality and morbidity
rates in patients with cardiovascular diseases.
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